INNA-051

Reducing the impact of viral respiratory infections and preventing severe complications in at-risk populations

ENA Respiratory is developing INNA-051, a first-in-class, small molecule prophylactic to minimise the impact of viral respiratory infections on patients and reduce the burden on the healthcare system.

INNA-051 is a novel, new chemical entity (small molecule) TLR2/6 agonist that boosts the body’s natural antiviral defenses. It is designed to eliminate the virus at the point of infection and prevent serious complications of respiratory viral disease.

Unmet medical need in high-risk populations

There is an urgent need to prevent respiratory viral illnesses/infections as they are amongst the most common causes of morbidity and mortality worldwide and a significant health burden to individuals at the greatest risk from exposure including the elderly, patients with underlying chronic illnesses and individuals in certain occupational roles.

Addressing Major Impact of Respiratory Infections

60+ million

individuals in the US alone

29.5 million

Adults (18-60y) in US with high-risk comorbidities

34.3 million

Adults (≥60y) in US with high-risk comorbidities

At Risk Populations Due to Comorbid Conditions

COPD, Asthma
Congestive Heart Failure
Chronic Kidney Disease
Diabetes
Lymphoma/Chronic Leukaemia
High-Dose Corticosteroids

At Risk Occupations

Healthcare workers
Teachers
Transportation workers
Military Personnel

INNA-051 highlights

Agnostic to specific viral pathogens and not susceptible to viral resistance mutations

Complementary to vaccines and antiviral medications and compatible with intranasal corticosteroids

Pre-clinical validation against influenza, rhinovirus & SARS-CoV2

Fast onset of action (‹ 24h) and durable biologic response supporting weekly dosing

Favourable safety profile in non-clinical safety, Phase I and Phase IIa studies, supporting seasonal prophylaxis application

Easy to use, one-weekly, self-administered nasal product

ENA is preparing for a Phase 2 study to demonstrate the safety and efficacy of INNA-051 in decreasing symptomatic respiratory viral infections in a community setting.